Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics
C. H. Hulton, E. A. Costa, N. S. Shah, A. Quintanal-Villalonga, G. Heller, E. de Stanchina, C. M. Rudin, J. T. Poirier
This study develops a CRISPR-Cas9 lentiviral platform for genome editing of patient-derived xenografts to analyze genetic dependencies and drug resistance mechanisms in vivo.
bioRxiv · Mar 26, 2019Cancer Biology